Google Groups no longer supports new Usenet posts or subscriptions. Historical content remains viewable.
Dismiss
Targeted Therapy in Cancer : An Update, by Marc Lacroix (2016)
5 views
Skip to first unread message
marc.lacr...@gmail.com
Jan 23, 2016, 12:34:09 PM1/23/16
to
Targeted Therapy in Cancer : An Update
https://www.novapublishers.com/catalog/product_info.php?products_id=57553
Author: Marc Lacroix
Pub. Date: 2016 - 2nd Quarter
Binding: Hardcover
https://www.novapublishers.com/catalog/product_info.php?products_id=57604
Authors: Marc Lacroix
Pub. Date: 2016
Binding: ebook
Abstract
Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of "targeted" therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval.
More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on.
A series of "companion" diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned.
The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients.
Table of contents
Preface
Chapter 1 Innovation in the Biopharmaceutical Pipeline
Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA
Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA
Chapter 4 Targeted Therapies: Detailed Description
Chapter 5 Targeted Therapies in the Pipe-Line
Chapter 6 Companion Diagnostics for Targeted Therapies
Abbreviations
Index
https://www.novapublishers.com/catalog/product_info.php?products_id=57553
Author: Marc Lacroix
Pub. Date: 2016 - 2nd Quarter
Binding: Hardcover
https://www.novapublishers.com/catalog/product_info.php?products_id=57604
Authors: Marc Lacroix
Pub. Date: 2016
Binding: ebook
Abstract
Besides surgery, radiation therapy, endocrine therapy or chemotherapy, which were widely used in cancer patients for decades, the 21st century has seen the emergence of "targeted" therapy, resulting from the identification of molecular pathways in cells and their alterations in tumors. An increasing number of compounds targeting specific molecules or cancer cells have been developed and, for some of them, approved by the United States Food and Drug Administration (FDA) as well as other regulators in EU and Japan Additional new and more efficient types of compounds, are still in clinical trials, but are expected to gain future approval.
More than eighty FDA-approved targeted therapies are described here, along with about eighty other promising compounds. These drugs are members of various therapy classes, including tyrosine kinase inhibitors; serine/threonine kinase inhibitors; dual specificity kinase inhibitors; lipid kinase inhibitors; poly ADP ribose polymerase inhibitors; monoclonal antibodies; microtubule targeting agents; histone deacetylase inhibitors; proteasome inhibitors; antimetabolites; immunomodulatory agents; DNA methyltransferase inhibitors; hedgehog pathway inhibitors; enzymes; protein translation inhibitors; vaccines, oncolytic viruses; chimeric antigen receptor T-cells (CAR-T); and so on.
A series of "companion" diagnostics intended to be used as an indication for specific therapies, and approved to this aim are also mentioned.
The book aims to present the broad landscape of compounds and companion diagnostics that are expected to pave the way towards a future of hope for cancer patients.
Table of contents
Preface
Chapter 1 Innovation in the Biopharmaceutical Pipeline
Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA
Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA
Chapter 4 Targeted Therapies: Detailed Description
Chapter 5 Targeted Therapies in the Pipe-Line
Chapter 6 Companion Diagnostics for Targeted Therapies
Abbreviations
Index
marc.lacr...@gmail.com
Jan 31, 2016, 8:09:35 AM1/31/16
to
Abiraterone, Ado-trastuzumab, Afatinib, Alemtuzumab, Algenpantucel-L, Alisertib, Alpelisib , Apatinib, ASP8273, Asparaginase, Atezolizumab, Avelumab, Axitinib, Azacitidine, AZD1775, Belinostat, Bevacizumab, Binimetinib, Bortezomib, Bosutinib, Brentuximab, Brigatinib, Buparlisib, Cabazitaxel, Cabozantinib, Carfilzomib, Cediranib, Ceritinib, Cetuximab, Crenolanib, Crizotinib, Custirsen, Dabrafenib, Dacomitinib, Dactolisib, Daratumumab, Dasatinib, Decitabine, Degarelix, Delanzomib, Denosumab, Dinaciclib, Dinutuximab, Dovitinib, Durvalumab, Duvelisib, Elotuzumab, Encorafenib, Entinostat, Enzalutamide, Eribulin, Erlotinib, Everolimus, Famitinib, Galunisertib, Ganetespib, Gefitinib, Glasdegib,GS-5745, GVAX pancreatic cancer vaccine, Ibritumomab, Ibrutinib, Idelalisib, Imatinib, Infigratinib, Ipilimumab, Ixabepilone, Ixazomib, JCAR015, KTE-C19, Lanreotide, Lapatinib, Lenalidomide, Lenvatinib, Luminespib, Marizomib, Masitinib, Midostaurin, Mogamulizumab, Momelotinib, Moxetumomab pasudotox, Necitumumab, Nelarabine, Nelipepimut-S, Neratinib, Nilotinib, Nintedanib, Niraparib, Nivolumab, Obinutuzumab, Ofatumumab, Olaparib, Omacetaxine, ONC201, Oprozomib, Osimertinib, Pacritinib, Palbociclib, Panitumumab, Panobinostat, Patritumab, Pazopanib, Pegaspargase, Pembrolizumab, Pemetrexed, Pertuzumab, Pexastimogene devacirepvec, Pexidartinib,Pomalidomide, Ponatinib, Pracinostat, Pralatrexate, Quizartinib, Ramucirumab, Regorafenib, Ribociclib, Rilimogene galvacirepvec (PROSTVAC), Rindopepimut, Rituximab, Rociletinib, Romidepsin, Rucaparib, Ruxolitinib, Savolitinib/Volitinib, Selumetinib, Sipuleucel-T, Sonidegib, Sorafenib, Sunitinib, Talazoparib, Talimogene laherparepvec (T-VEC), Taselisib, Tasquinimod, Temsirolimus, Tergenpumatucel-L (HyperAcute Lung), Tivantinib, Tivozanib, Tositumomab, Trametinib, Trastuzumab, Tremelimumab, Vandetanib, Veliparib, Vemurafenib, Venetoclax, Vismodegib, Volasertib, Vosaroxin, Voxtalisib
0 new messages